Search Results



Your search for all items matches 1885 pages

Showing 1 - 50


breast cancer

Alcohol Consumption May Be Associated With Higher Risk of Breast Cancer in African American Women

Alcohol intake was associated with an increased risk of breast cancer in a large study of African American women, indicating that they, like white women, may benefit from limiting their alcohol consumption, according to results of a study published by Williams et al in Cancer Epidemiology,...

breast cancer

Study on Women Living With Metastatic Breast Cancer

A study by Mariotto et al investigating the prevalence of women living with metastatic breast cancer in the United States estimates that there are 154,794 women living with the disease. In addition, the median and 5-year relative survival for women initially diagnosed with metastatic breast...

breast cancer

Long-Term Follow-up of Intergroup Exemestane Study

A final efficacy analysis of the Intergroup Exemestane Study, reported in the Journal of Clinical Oncology by Morden et al, shows continued benefit of switching to adjuvant exemestane after 2 to 3 years of tamoxifen in patients with early breast cancer. Study Details In the trial, patients who...

breast cancer

Hypofractionated Postmastectomy Radiation in Breast Cancer

In a phase II trial, Khan et al found that hypofractionated postmastectomy radiotherapy, completed in 15 treatment days, was safe and effective in women with stage II to IIIa breast cancer. The study was reported in the Journal of Clinical Oncology. Study Details In the study, 67 women from 2...

breast cancer

Changes in HER2 Breast Cancer Testing According to 2007 and 2013 ASCO/CAP Guidelines

Hanna et al have reported that the 2013 update to the 2007 ASCO/College of American Pathologists (CAP) recommendations for HER2 testing in breast cancer did not result in changes in the overall HER2-positivity rate but was associated with a higher rate of equivocal results. Their findings were...

breast cancer

Adding Pertuzumab to Trastuzumab/Capecitabine in Pretreated HER2-Positive Metastatic Breast Cancer

The phase III PHEREXA trial has shown no significant improvement in progression-free survival with the addition of pertuzumab (Perjeta) to trastuzumab (Herceptin)/capecitabine in patients with HER2-positive metastatic breast cancer with disease progression during or after trastuzumab-based...

breast cancer

FDA Approves Ribociclib/Letrozole Co‑Pack for Postmenopausal Patients With Advanced or Metastatic Breast Cancer

On May 8, the U.S. Food and Drug Administration (FDA) approved the copackaging of ribociclib (Kisqali) and letrozole (Femara) tablets for the treatment of hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in postmenopausal ...

Breast Cancer
Symptom Management

Saving My Hair Changed My Perception of Having Cancer

Getting a callback after a routine screening mammogram in 2013 did not set off any alarm bells. Having dense breasts has almost guaranteed receiving the dreaded callback ever since I started getting annual screenings. But when I got a second callback after additional images of a suspicious lesion...

breast cancer

Final, 10-Year Follow-up of Phase III Trial on Adding Gemcitabine to Adjuvant Therapy in Breast Cancer

The final, 10-year follow-up of the ‘all comers’ tAnGo trial, reported by Earl et al in The Lancet Oncology, continued to show no overall benefit of adding gemcitabine to adjuvant therapy in women with early-stage breast cancer. The trial, initiated in 2001, included patients...

Breast Cancer

Expert Point of View: Kelly M. McMasters, MD, PhD

“More and more, we are finding that traditional anatomic TNM staging has significant limitations in predicting prognosis, especially in such cases where response to therapy is an important consideration,” commented session moderator Kelly M. McMasters, MD, PhD, a surgical oncologist at the...

Breast Cancer

Neo-Bioscore Improves Staging of Breast Cancer Treated With Neoadjuvant Chemotherapy

A new score that incorporates tumor biology and response outperforms conventional histopathologic criteria for the staging of breast cancer treated with neoadjuvant chemotherapy, finds a retrospective validation cohort study.1 Investigators led by John R. Bergquist, MD, MS, MA, a general surgery...

breast cancer

IMPAKT 2017: Few Variations in Somatic Mutations Observed Between Pregnant and Nonpregnant Patients With Breast Cancer

Findings comparing the mutational landscape in pregnant and nonpregnant patients with breast cancer that sought to define whether the disease may have a different biology in pregnant women were reported by Loibl et al at the 2017 IMPAKT Breast Cancer Conference, held in Brussels (Abstract...

breast cancer

IMPAKT 2017: Luminal Androgen Receptor Subtype of Triple-Negative Breast Cancer Demonstrates Sensitivity to CDK4/6 Inhibition

Researchers have identified a subtype of triple-negative breast cancer that may be responsive to inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6), according to findings presented by Asghar et al at the 2017 IMPAKT Breast Cancer Conference, held in Brussels (Abstract 44P). This study also...

breast cancer

IMPAKT 2017: High Baseline Tumor-Infiltrating Lymphocyte Levels Signal Superior Responses in HER2-Positive Breast Cancer

Baseline levels of tumor-infiltrating lymphocytes (TILs) in pretreatment biopsies from patients with HER2-positive breast cancer are significantly associated with pathologic complete response rates following neoadjuvant chemotherapy plus anti-HER2 agents (trastuzumab [Herceptin], lapatinib...

breast cancer

Germline Genetic Testing and Treatment Decisions in Early-Stage Breast Cancer

As reported in the Journal of Clinical Oncology by Kurian et al, surveys in a population-based sample of patients recently diagnosed with breast cancer indicate that many undergo genetic risk testing without seeing a genetics counselor and that many with BRCA1/2 variants of uncertain significance...

Breast Cancer

Selected Clinical Trials of CDK4/6 Inhibitors

This Clinical Trials Resource Guide includes a selection of actively recruiting clinical trials of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, ribociclib, and abemaciclib in multiple tumor types. All of the studies here and many others are listed on the National...

Breast Cancer

First-in-Human Experience With Abemaciclib

The investigational cyclin D–dependent kinase (CDK) 4/6 inhibitor abemaciclib was recently evaluated in several solid tumor types in a phase I multicenter trial.1 Given primarily as a single agent and with continuous dosing, abemaciclib showed encouraging early signals of clinical activity not only ...

Breast Cancer

CDK4/6 Inhibitors: Where They Are Now and Where They Are Headed in the Future

Geoffrey I. Shapiro, MD, PhD, Director of the Early Drug Development Center at the Dana-Farber Cancer Institute, Boston, explained the current research initiatives involving cyclin D–dependent kinase (CDK) 4/6 inhibitors. Mechanism of Action How do CDK4/6 inhibitors work at the cellular level in...

Breast Cancer

CDK4/6 Inhibitors: Their Role in Breast Cancer

The robust progression-free survival benefits achieved with the use of the CDK4/6 inhibitors palbociclib or ribociclib in the metastatic setting provided the impetus to study these agents in early-stage breast cancer. Adjuvant studies are underway, but they take time to mature. For evaluating...

Breast Cancer

Introduction: CDK4/6 Inhibitors: Moving Beyond the Breast Cancer Setting

The novel mechanism of action of drugs that inhibit the cyclin D–dependent kinases CDK4 and CDK6 has prompted effective new treatment strategies. Although the bulk of the data supporting the use of selective CDK4/6 inhibitors is currently in breast cancer, patients with other tumor types are...

Breast Cancer

Continuing Education Information

This CE/CME/CEU-accredited supplement is jointly provided by           To earn credit/contact hours, you must read all the articles in this supplement and then go to: https://education.annenberg.net/cdk46inhibition Release date: May 10, 2017 Expiration date: May 10, 2018Annenberg Center for Health...

breast cancer

Benefit of Survivorship Care Plans Among Low-Income, Predominantly Latina Breast Cancer Survivors

A randomized trial, reported by Maly et al in the Journal of Clinical Oncology, has shown that having an individualized survivorship care plan in place was associated with increased physician implementation of recommended breast cancer survivorship care among low-income, predominantly Latina breast ...

breast cancer

New 'Bone-in Culture Array' Tests Therapies for Breast Cancer Metastasis

A new laboratory technique developed by researchers at Baylor College of Medicine and other institutions can rapidly test the effectiveness of treatments for life-threatening breast cancer metastases in bone. Findings of this research were published by Wang et al in Nature Communications....

breast cancer
symptom management

Joint Position Statement on Management of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Hormone-Sensitive Breast Cancer

A new position statement, jointly published by seven international and European organizations, identifies fracture-related risk factors in patients treated with aromatase inhibitors and outlines key management strategies to help prevent bone loss and related fractures. It was published by Hadji et...

breast cancer
supportive care
integrative oncology

Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment

In newly updated clinical guidelines from the Society for Integrative Oncology (SIO), researchers at Columbia University's Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center, along with an interdisciplinary team of colleagues at The University of Texas MD Anderson...

breast cancer

Neoadjuvant Chemotherapy for Breast Cancer and Risk for Local Metastases

A pathologic complete response to presurgical therapy occurs in between 40% and 50% of patients with HER2-positive and triple-negative breast cancer, raising the question of the need for surgery for all patients after neoadjuvant chemotherapy indicates a pathologic complete response in...

breast cancer

Multigene Test Could Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer

New research indicates that testing for variants in seven cancer-associated genes (instead of the usual process of testing in just two genes) followed by risk-reduction management could cost-effectively improve life expectancy for women at risk of hereditary breast cancer. The findings were...

breast cancer

Efficacy Analysis of ABC Breast Cancer Trials of Adjuvant Taxane With/Without Anthracycline in HER2-Negative Disease

As reported by Blum et al in the Journal of Clinical Oncology, the efficacy analysis of the combined adjuvant Anthracyclines in Early Breast Cancer (ABC) Trials showed better invasive disease-free survival with taxane plus doxorubicin/cyclophosphamide (TaxAC) regimens vs six cycles of...

breast cancer

Breast Cancer Rates Increasing Among Asian Americans

In contrast to other racial/ethnic groups in the United States, Asian Americans have experienced steadily increasing breast cancer rates over the past 15 years, according to findings published by Gomez et al in Breast Cancer Research and Treatment. To better understand potential contributors to...

breast cancer

21-Gene Assay Score and Chemotherapy Decision-Making in Node-Positive Early Breast Cancer

The 21-gene recurrence score assay, Oncotype DX, determines a score that estimates the likelihood of distant recurrence of disease in women with early-stage estrogen receptor–positive breast cancer; this score is used to assess the benefit of adjuvant chemotherapy. Testing with this assay is...

Breast Cancer

Fear Has Become a Big Part of My Survivorship

Just 32 when I first felt a lump in the top of my left breast, I never expected it to be cancer or my life would irrevocably change in that instant. With no history of breast cancer in my family, I initially shook off any thoughts that I could have a serious disease and instead consoled myself...

Breast Cancer
Cost of Care

Trastuzumab Biosimilar Could Lead to Lower Health-Care Costs and Greater Drug Access for Patients With Metastatic Breast Cancer

The human epidermal growth factor receptor (HER) family consists of four members—epidermal growth factor receptor (EGFR), HER2, HER3, and HER4—all transmembrane receptor tyrosine kinases, which regulate cell growth and survival, differentiation, and migration, as well as other cellular responses.1 ...

Breast Cancer

Equivalent Response Rates With Trastuzumab or a Trastuzumab Biosimilar Plus Taxane in HER2-Positive Metastatic Breast Cancer

In part 1 of the Heritage study, a phase III equivalence trial reported in JAMA, Hope S. Rugo, MD, of the University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, and colleagues found that treatment with trastuzumab (Herceptin) or a proposed trastuzumab biosimilar...

Breast Cancer

Expert Point of View: Steven L. Chen, MD

“Dr. Neuman and colleagues point out that patients often will seek out information on their diagnosis preconsultation,” commented session co-moderator Steven L. Chen, MD, a surgical oncologist with OasisMD in San Diego. “Their study demonstrates that the provision of high-quality information can...

Breast Cancer

Decision Aid Improves Breast Cancer Patients’ Knowledge of Surgical Options

A Web-based decision aid that allows women with early breast cancer to easily compare surgical treatment options helps them make more informed decisions, suggests a randomized trial reported at the 2017 Society of Surgical Oncology (SSO) Annual Cancer Symposium.1 “Having knowledge of surgical...

Breast Cancer

Resilience Linked to Less Distress in Lesbian and Bisexual Breast Cancer Survivors

Breast cancer can have a pervasive effect on a woman’s psychological functioning, but sexual minority (ie, lesbian and bisexual) breast cancer survivors are underrepresented in studies of psychological distress, according to Charles Kamen, PhD, a clinical psychologist at the University of Rochester ...

breast cancer

Effect of Radiotherapy Boost for Ductal Carcinoma in Situ After Whole-Breast Radiotherapy

In an analysis reported in JAMA Oncology, Moran et al found that a radiotherapy boost for ductal carcinoma in situ with local control after whole-breast radiotherapy was associated with a reduction in the risk for ipsilateral breast tumor recurrence. Study Details The analysis pooled...

breast cancer

Satisfaction With Surgical Decision-Making in Women Considering Contralateral Prophylactic Mastectomy for Breast Cancer

In a study reported in JAMA Surgery, Katz et al found that most patients considering contralateral prophylactic mastectomy for stage 0 to II breast cancer were satisfied with surgical decision-making. Most surgeons discussed contralateral prophylactic mastectomy and most did not recommend against...

breast cancer

Breast Cancer Treatment Options Vary Widely in Cost-Effectiveness

A study published by Smith et al in the Journal of the National Cancer Institute indicates that different therapies for early-stage breast cancer have very different relative values. Some therapies may have fewer complications and be much less expensive than others. Women may be making treatment...

breast cancer

AACR 2017: Interim Results of Phase Ib/II Trial of Neratinib in Combination With Ado-trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

Interim results from the phase Ib/II FB-10 clinical trial of neratinib given in combination with the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1, Kadcyla) were reported in a poster at the 2017 American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, according...

breast cancer

Patient-Reported Outcomes With Immediate Implant-Based or Autologous Breast Reconstruction

As reported in the Journal of Clinical Oncology by Pusic et al, patient-reported outcomes in the Mastectomy Reconstruction Outcomes Consortium Study indicate that autologous tissue breast reconstruction is associated with greater breast satisfaction and greater sexual and psychosocial well-being...

Breast Cancer

Ribociclib in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

On March 13, the cyclin-dependent kinase (CDK) 4/6 inhibitor ribociclib (Kisqali) was approved for use in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast ...

Breast Cancer

Young Women With Metastatic Breast Cancer: Unique Needs and Concerns

Patients with breast cancer who perceive having enough and the right kinds of social support tend to be less stressed, although a paucity of research exists on the social support needs of young women with metastatic breast cancer, according to Amanda Ginter, PhD. Dr. Ginter, Assistant Professor in ...

breast cancer

AACR 2017: Patients With Triple-Negative Breast Cancer Who Responded to Atezolizumab Had Long-Term Survival Benefit

Among patients with metastatic triple-negative breast cancer who were treated with the anti–programmed death-ligand 1 (PD-L1) immunotherapy atezolizumab (Tecentriq), those who responded to the treatment had a longer overall survival compared with those who did not respond, according to data...

breast cancer

Palbociclib Receives FDA Approval and Expanded Indication for First-Line Metastatic Breast Cancer

On March 31, the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for a first-in-class cyclin-dependent kinase (CDK) 4/6 inhibitor, palbociclib (Ibrance), based on the results from the confirmatory phase III trial PALOMA-2. The FDA action converts the...

breast cancer

Racial and Ethnic Disparities in Gene-Expression Profiling Tests in Breast Cancer

For a proportion of patients, including women with hormone receptor–positive breast cancer, gene-expression profiling has a substantial impact on treatment decision-making by determining which patients might—or might not—respond to particular treatment options. Gene-expression...

breast cancer

Anti–Trop-2 Antibody Drug Conjugate in Heavily Pretreated Metastatic Triple-Negative Breast Cancer

As reported in the Journal of Clinical Oncology by Bardia et al, the anti–Trop-2 antibody drug conjugate sacituzumab govitecan has been found to produce durable responses in patients with heavily pretreated metastatic triple-negative breast cancer. Trop-2, a glycoprotein initially identified ...

breast cancer
gynecologic cancer

Significant Increase in Number of Women Tested for BRCA Gene, but Many High-Risk Patients Remain Unidentified

About 5% to 10% of breast cancer cases and 10% to 18% of ovarian cancer cases can be attributed to two BRCA genetic mutations. Testing for these genetic abnormalities has risen steadily over the past decade. Previously, mainly women with a history of cancer were referred for genetic testing, but as ...

breast cancer

Effect of Polypharmacy on Adherence to Adjuvant Endocrine Therapy for Breast Cancer

In a retrospective cohort study reported in the Journal of Oncology Practice, Calip et al found that polypharmacy overall was associated with increased adherence to adjuvant endocrine therapy for breast cancer. However, frequent use of some medication classes was associated with decreased...

breast cancer

Impact of 70-Gene Signature on Adjuvant Chemotherapy Decisions in Breast Cancer

In a Dutch observational study reported in the Journal of Clinical Oncology, Kuijer et al found that use of the MammaPrint 70-gene signature (70-GS) test changed physician-intended recommendations to administer adjuvant chemotherapy in half of patients with early-stage estrogen...

Advertisement



Advertisement


Advertisement

click me